Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2014  |  Volume : 10  |  Issue : 2  |  Page : 239-243

The role of serum carcinoembryonic antigen in predicting responses to chemotherapy and survival in patients with non-small cell lung cancer


1 Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China
2 Jiangsu Province Geriatric Hospital, Jiangsu Province Geriatric Institute, Nanjing, China

Correspondence Address:
Yong Song
Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing 210002 Jiangsu Province
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.136541

Rights and Permissions

Background: Previous studies indicated that carcinoembryonic antigen (CEA) could predict the therapeutic objective response (OR) and overall survival (OS) of patients with cancers, including non-small cell lung cancer (NSCLC). However, the role it could play in evaluating therapeutic responses and OS in patients with NSCLC requires further elucidation. Herein, we investigated the potential role of CEA in predicting OR and OS in patients with NSCLC. Materials and Methods: For this retrospective study, the medical records of 689 patients with NSCLC who were treated at Nanjing Jinling Hospital between January 2000 and August 2011 were reviewed. Serum levels of CEA of these patients were measured before and after chemotherapy. The relatedness between CEA levels and OR, and between CEA and OS were investigated for correlations via a series of statistical analyses. Results: The baseline serum CEA level of 689 patients was 54.18 ± 143.45 ng/mL. Serum CEA significantly decreased after two cycles of chemotherapy (t = 2.196, P = 0.031). The receiver operator characteristic (ROC) curve analysis showed that a 5.28% reduction in CEA level was an appropriate cut-off value for predicting the OR to chemotherapy, with a sensitivity of 61.3% and a specificity of 62.4%. The Kaplan-Meier survival analysis indicated no significant correlation between baseline CEA and OS (P = 0.079). Conclusion: Our study shows that while the baseline level of CEA was not a prognostic factor, the post-treatment reduction of CEA can predict the OR in patients with NSCLC.

Abstract in Chinese

血清癌胚抗原在预测非小细胞肺癌患者化疗反应和生存的作用 摘要 背景:研究表明,癌胚抗原(CEA)可以预测包括非小细胞肺癌(NSCLC)癌症患者治疗的客观疗效(OR)和总生存期(OS)。然而,它可以在评估NSCLC患者OR和OS发挥作用需要进一步的澄清。在这里,我们研究了CEA预测非小细胞肺癌(NSCLC)患者OR和OS的潜在作用。 材料与方法:本回顾性研究中,对南京金陵医院2000年1月到2011年8月间治疗的689例NSCLC患者的医疗记录进行了回顾。这些患者都检测了化疗前后血清CEA的水平。CEA水平与OR的关系,以及CEA和OS之间的相互关系进行了一系列的统计分析。 结果:689例病人的基线血清CEA水平为54.18±143.45ng/ml。化疗2个周期后血清CEA明显降低(t = 2.196,P = 0.031)。ROC曲线分析表明,CEA水平降低5.28%是一个适当的截断值,在预测化疗的治疗反应(OR)方面,敏感性为61.3%,特异性为62.4%。Kaplan-Meier生存分析显示基线CEA和OS无显著相关性(P = 0.079)。 结论:CEA基线水平并不是一个预后因子,而治疗后CEA降低程度可以预测NSCLC患者的治疗客观反应(OR)。 关键词:癌胚抗原,非小细胞肺癌,客观疗效,整体存活率



[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2333    
    Printed84    
    Emailed1    
    PDF Downloaded107    
    Comments [Add]    

Recommend this journal